A dangerous, drug-resistant fungus known as Candida auris is spreading globally. Research published this month indicates that the public health threat posed by C. auris has been rising steadily.
Scientists examined existing literature on C. auris, which was first identified in 2009. Since its discovery, outbreaks have occurred worldwide, including in the United States. This infection is often mistaken for other types of infections and is challenging to treat with current medications, which increases its threat level.
The authors of the study stated that we need to create innovative antifungal treatments that target a broad range of human fungal pathogens, improve diagnostic methods, and explore immune- and vaccine-related treatments for high-risk patients. This research was detailed in a paper published in the journal Microbiology and Molecular Biology Reviews.
The rising fungal menace
Fungal infections are becoming a more significant threat to public health. A study from last year estimated that fungi may contribute to nearly 4 million deaths each year, nearly double the figure from a decade ago. Yet, C. auris—first discovered in a patient’s ear in Japan in 2009—stands out as particularly concerning.
C. auris can live on human skin without causing issues, but in individuals with weakened immune systems, it can lead to severe and rapidly life-threatening infections. About one-third of hospitalized patients infected with C. auris may die from it, while the mortality rate for bloodstream infections can soar to nearly 50%.
A significant factor contributing to the danger of C. auris is its resilience against many commonly used antifungal treatments. There have been instances of pan-resistant strains that resist all major antifungal classes. Additionally, standard testing often misidentifies C. auris as other species, resulting in delays or incorrect treatments.
While C. auris remains a relatively uncommon cause of fungal infections, its prevalence is clearly rising, as noted by the study’s researchers. It has been documented in over 50 countries, and in the U.S., at least 39 states have reported C. auris cases in healthcare settings, with over 4,500 cases reported in 2023.
More chillingly, some researchers suggest that C. auris may be one of the first emerging diseases linked directly to climate change. Evidence indicates that it began infecting humans more frequently after adapting to warmer temperatures, resembling those found in the human body.
Not all hope is lost
Despite the alarming developments, there is still room for hope.
Researchers emphasize that new antifungal treatments are in the works, and several promising drugs are either reaching the market or advancing in development. In 2023, the FDA approved Rezafungin for treating invasive Candida infections. There are also advancements in vaccines that could help protect against a wider array of fungal pathogens.
The researchers aim to not just share what they know about C. auris but also hope to discover future measures to combat such harmful germs.
Neeraj Chauhan, a professor at the Center for Discovery and Innovation at Hackensack Meridian Health in New Jersey, stated, “My lab studies how fungal pathogens interact with their hosts to cause infections, aiming to reveal the molecular mechanisms that let these organisms thrive.” He added that the long-term goal is to help develop new methods for identifying, preventing, and treating drug-resistant fungal infections.
With any luck, scientists like Chauhan will uncover the vulnerabilities of C. auris before we face scenarios reminiscent of fungal nightmares seen in media, like The Last of Us.
